OKYO Pharma Stifel 2026 Healthcare Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good morning, everyone, and welcome to the OKYO Pharma presentation. OKYO is an ophthalmology company developing a treatment for neuropathic pain, and I am happy to have Robert Dempsey, CEO of OKYO, here to present the company. Robert, take it away. We will for Q&A at the end.
Thank you very much, and thank you for the Stifel team for the opportunity to present. My name is Robert Dempsey, and I am the CEO of OKYO Pharma. At OKYO, we are focused on addressing unmet needs in corneal and anterior segment diseases of the eye. We believe we have a differentiated therapeutic approach targeting a potential blockbuster-scale market opportunity of which there are no FDA-approved programs. We are a publicly traded company. Big news, on the cusp of the American Academy of Ophthalmology in early October, we announced the first subjects were enrolled in our pivotal phase III trial, referred to as the NEPTUNE trial, for patients with neuropathic corneal pain. What I would like to do is set the stage where we are today. We believe at OKYO, we are pioneering a new ocular therapeutic market with urcosimod.
urcosimod is a novel non-opioid preservative-free eye drop with a dual pain-relieving as well as anti-inflammatory activity for patients with neuropathic corneal pain. Let us set the stage for patients with neuropathic corneal pain. First and foremost, this is a severe debilitating condition in which there is significant impact on patients' quality of life, of which there is no FDA-approved program. These patients commonly experience pain, photophobia, and unfortunately, a constant burning and foreign body sensation, and as mentioned, significantly impacting the patient's quality of life. Our approach is a novel mode of action with urcosimod that targets the ChemR23 receptor on the corneal surface, which is a differentiated dual mechanism that modulates both neuropathic pain signaling as well as immune-mediated inflammation. Why are we so excited?
Under the direction of Dr. Pedram Hamrah at Tufts Medical Center in Boston, he conducted a proof-of-concept study in which urcosimod demonstrated a clinically meaningful reduction in pain, of which we saw a 5.5 improvement utilizing the 10-point VAS score. The VAS score is a visual analog scale that has a scale of 0, no pain, to 10, the most excruciating pain that one can imagine. What we saw is that 75% of patients achieved a greater than 80% improvement in their pain. As I like to say, the good news does not stop there in the symptom relief of these patients. We also saw a strong effect on the patient's nerves, on the nerve plexus, in which we signaled the potential for corneal nerve restoration. As you can imagine, the patients had a significant relief in their symptom of pain.
We saw a strong signal in the sign of nerve regeneration, while we also saw an improvement in these patients' quality of life, which we believe is an important measure of the impact of this drug. From a safety perspective, the drug is well tolerated, and we didn't see any serious adverse events in any of the clinical trials that we've done. We're also very excited about the development plan moving forward. As mentioned, we have activated our phase III NEPTUNE trial, and this study will enroll approximately 111 subjects in a 2-to-1 randomization schedule compared to placebo. As you can imagine, going into phase III, we had to develop our commercial-grade study lot, which we've done, and we expect to have top-line data now that we've initiated the study in the back half of next year.
Our engagements with the agency have gone very well, in which we have the first and only IND that's been awarded in this space, as well as Fast Track designation. In discussions with Dr. Bill Boyd, Director of the agency ophthalmology division, we have confirmed our primary endpoint being the VAS score. We have confirmed our sample size being approximately 111 subjects in this trial, and the fact that this is the potential pivotal trial for FDA approval. The team has worked extensively on our intellectual property, and we have IP protection through at least 2039. I'm also very excited about the commercial research that we've done. We believe there's a robust market potential for this opportunity, and as you can see here, potential blockbuster-scale market opportunity.
The ongoing market research, as I like to say, has jumped off the page, in which the eye care professionals and payers are signaling the opportunity for a premium pricing strategy. We'll have more information on that in a few moments. Since joining in January, we've engaged institutional investors. We had a raise of approximately $22 million all in. I'll call your attention to the institutional investors. Bringing in this group of institutional investors, both during the raise as well as in the open market, is a strong signal of a validation. Why? Because these are ophthalmology investors. They have over 30 positions in the ophthalmology space. With the raise that we did, we are well capitalized through the clinical study well into 2027. From a development pipeline perspective, obviously we're very excited to be in phase III.
Our Chief Medical Officer, our Chief Development Officer, and I are looking at other opportunities to de-risk this opportunity. We believe, based on the mode of action of urcosimod, there are opportunities in rare corneal diseases. We're in the process of exploring these opportunities to help diversify our portfolio. What I'd like to do now is take a look at this market, the disease background, the patient journey, as well as the commercial opportunity. First and foremost, this condition, neuropathic corneal pain, is significantly under-researched with a substantial impact on the patient's quality of life. Unfortunately, it's an ill-defined disease that presents with pain, oftentimes not only in the eye, but in the head and the face. As mentioned, it's a debilitating pain.
As you can imagine, the highest concentration of nerves are on your corneal surface, and when they are inflamed and when they are damaged, there is a significant impact on patients' quality of life and, unfortunately, their ability to work. From a standpoint of medical education, it is a challenge to diagnose for the ophthalmic community. Hence, as we have entered phase III, we are engaging both sides of the ophthalmology and optometry, as I like to say, both sides of the aisle, to help from a medical educational perspective. As mentioned, it is an underserved market of which there is no FDA-approved program. The treatments, so we have done a lot of research from this perspective, and unfortunately, because there is no FDA-approved program, physicians are treating patients with non-steroidals, with steroids, with serum tears, and unfortunately, in severe cases, they are using oral medications.
I can assure you, spending 30 years in the ophthalmology space, ophthalmologists do not like using pain medications and oral medications to treat these patients. Let us kind of look at the patient journey. I think it is very important to point out that the initial presentation is oftentimes with a primary care physician, and obviously they refer them quickly to an eye care specialist, whether it is an optometrist and/or ophthalmologist. One of the things we have learned in our market research, it is difficult for the, quote unquote, "general eye care physicians" to diagnose these patients, ultimately leading these patients to a more specialized ocular healthcare professional at an academic center in which they can do more extensive evaluation, the proparacaine challenge, and in some cases, utilizing the confocal microscope to look at the integrity of the nerves to see if they are actually damaged and dysfunctional.
Bottom line, patients are frustrated because of the misdiagnosis and oftentimes going from physician to physician. As you can imagine, the physicians are also frustrated with the lack of knowledge and diagnostic tools to make this actual diagnosis. Bottom line, delaying this diagnosis results in patients progressing to centralized pain, which could be much more difficult for these physicians to treat these patients. As mentioned, very excited about our commercial work. Our commercial assessment and pricing strategy is on track. From a market characterization perspective, no FDA-approved program, no ICD-10 code. We have done extensive work from an epidemiology perspective to understand this market, working with two of the best companies in the space, Komodo and Verana, and working with the IRIS Registry to get a better understanding of the market potential and market size.
We should have that data done, excuse me, completed by the end of the year. From a commercial perspective, we have completed the target product profile, and that is in the field literally as we speak. Based on some of the early reports from the eye care professionals, we see a strong endorsement of this target product profile. In addition, we have also met with payers, and what the payers are signaling is the opportunity for a premium pricing strategy. Obviously, there is an important comp in this space with the great work our friends have done at Dompé with the drug OXERVATE for a similar condition of the corneal surface neurotrophic keratitis. We believe based on the comps, based on the target product profile, and based on the receptivity, it has been very strong to date. Why is that? Well, first of all, severe debilitating condition in which there's significant impact on patients' quality of life, no FDA-approved program, and the fact that we have a novel first-in-class opportunity here, and a product that targets both inflammation and pain.
Last but not least, as you start on the patient journey, prescribed by cornea specialists. We believe all this comes to the conclusion that there's a premium pricing potential and the potential for profitable access per treatment cycle. As mentioned, ophthalmologists, and in some cases optometrists, do not like using oral medications. When we're doing our analysis, one of the oral medications that's used most often is gabapentin. Unfortunately, it's prescribed off-label. Multiple states have restricted the use of this program, and there's a growing concern around dependence and misuse of using gabapentin to treat patients with neuropathic corneal pain.
Hence, there's a lot of anxiety and concern and need for a program that can treat these patients. Now what I'd like to do is transition into the mode of action as well as the clinical rationale. First and foremost, urcosimod. It's a lipidated peptide designed to selectively target the MrgprX2 receptor, which is a key regulator of ocular pain and inflammation. Urcosimod has demonstrated both in animal models as well as humans, both analgesia as well as anti-inflammatory activity. The MrgprX2 receptor is a key regulator of neuropathic pain signaling as well as ocular inflammation. I'll call your attention to the right-hand side of the screen, which gives a nice graphical representation of the molecule. Bottom line, this is a first-in-class MrgprX2 receptor agonist that offers a dual mechanism of action. Transitioning to how we got to neuropathic corneal pain.
The original work was done in dry eye disease, and having spent some time in the space, I know it very well. It's crowded and can be somewhat difficult to differentiate programs. As the company was doing an analysis of the data, they saw that urcosimod demonstrated a significant relief in pain in this dry eye study. What's interesting is this study was not enriched to show a difference in pain, yet to do that in this study was a very important opportunity for the company to pivot into neuropathic corneal pain. Plus, we conducted a mouse model that looked at the effect of urcosimod compared to gabapentin. To set this up, the animals had a nerve ligation model to create neuropathic corneal pain in the mouse, and they applied urcosimod to the corneal surface as well as IP delivery of gabapentin.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
